Viviana Moschese
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Viviana Moschese has a total of 394 co-authors. Here are the top co-authors by number of shared publications:
- Mayla Sgrulletti
Pediatric Immunopathology and Allergology Unit, Policlinico Tor Vergata, University of Rome Tor Vergata, 00133 Rome, Italy
15 shared publications - Caterina Cancrini
Research Unit of Primary Immunodeficiencies, Bambino Gesu’ Children’s Hospital, IRCCS, Italy
8 shared publications - Silvia Di Cesare
University Department of Pediatrics, Unit of Immune and Infectious Diseases, Childrens' Hospital Bambino Gesù, Italy
8 shared publications - Gigliola Di Matteo
Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy
7 shared publications Loredana Chini
Pediatric Immunopathology and Allergology Unit University of Rome Tor Vergata Policlinico Tor Vergata Rome Italy
7 shared publicationsBaldassarre Martire
6 shared publications
Latest Publications
- Open Access
- 22 October 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (6)
Work participation in inborn errors of immunity: The dual burden on patients and caregivers
Despite improved survival, occupational challenges in with inborn errors of immunity (IEI) patients and their families remain unmeasured. We conducted a nationwide cross-sectional survey promoted by AIP and ImmunITA, including 420 IEI adults and 110 caregivers, integrating occupational data with patient-reported outcome measures. Multivariable models assessed employment and productivity determinants. Overall, 67% of patients were employed, yet half reported reduced capacity, unsafe environments, limited career progression, and stigma. Unemployment was associated with female sex, disability, and lower education. Nondisclosure affected one-fourth of patients and one-fifth of caregivers. Work impairment reached 39%; absenteeism was driven by healthcare demands, while presenteeism was associated with disease burden, psychological distress, and immune dysregulation, but not the Ig administration route. Caregivers showed 34% work impairment, with absenteeism linked to care intensity and presenteeism to psychological distress, patient health, and child caregiving. Child caregivers had greater time demands and more part-time employment. In conclusion, IEI substantially impair work productivity, supporting integration of occupational needs into care to improve social inclusion.
- 22 October 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (6)
Open AccessWork participation in inborn errors of immunity: The dual burden on patients and caregivers
Despite improved survival, occupational challenges in with inborn errors of immunity (IEI) patients and their families remain unmeasured. We conducted a nationwide cross-sectional survey promoted by AIP and ImmunITA, including 420 IEI adults and 110 caregivers, integrating occupational data with patient-reported outcome measures. Multivariable models assessed employment and productivity determinants. Overall, 67% of patients were employed, yet half reported reduced capacity, unsafe environments, limited career progression, and stigma. Unemployment was associated with female sex, disability, and lower education. Nondisclosure affected one-fourth of patients and one-fifth of caregivers. Work impairment reached 39%; absenteeism was driven by healthcare demands, while presenteeism was associated with disease burden, psychological distress, and immune dysregulation, but not the Ig administration route. Caregivers showed 34% work impairment, with absenteeism linked to care intensity and presenteeism to psychological distress, patient health, and child caregiving. Child caregivers had greater time demands and more part-time employment. In conclusion, IEI substantially impair work productivity, supporting integration of occupational needs into care to improve social inclusion.
- Open Access
- 7 October 2026
- Published by MDPI AG in Preprints.org
Use of Dupilumab in Pediatric Atopic Dermatitis and in Inborn Errors of Immunity-Associated Atopic Skin Disease: An Italian Society of Pediatric Research (SIRP) Multicenter Real-World Study
Background: Atopic dermatitis (AD) is generally considered polygenic but may occur as a predominant manifestation of inborn errors of immunity (IEI). Although dupilumab is effective in pediatric AD, evidence in IEI-associated severe atopic skin disease remains limited, with no longitudinal comparative studies available. We aimed to characterize clinical phenotype and compare effectiveness, quality-of-life, and safety of dupilumab in pediatric patients with severe polygenic AD and IEI-associated severe atopic skin disease. Methods: This multicenter retrospective observational study within the Italian Society of Pediatric Research Network included children and adolescents who initiated dupilumab before 18 years of age. Given IEI rarity, we accepted a numerically unbalanced but clinically meaningful cohort. Clinical outcomes were assessed longitudinally using EASI, pruritus NRS, and CDLQI scores. Achievement and maintenance of EASI-50/75/90 re-sponses were evaluated, together with adverse events and treatment discontinuation. Results: Among 127 patients, 116 had polygenic AD and 11 had IEI-associated disease. IEI patients more frequently had disease onset within 6 months (64% vs. 29%; p=0.037), severe recurrent infections (100% vs. 0%; p< 0.001), very elevated sIgE (91% vs. 14%; p< 0.001), and higher baseline EASI (median 50 vs. 25; p< 0.001). EASI, pruritus, and CDLQI improved significantly over time. EASI-50/75/90 were achieved by 88.2%/81.9%/66.1% and maintained by 84.3%/69.3%/47.2%. IEI patients showed steeper EASI decline but achieved EASI-75/90 later. Dupilumab was well tolerated with no unexpected safety signals. Conclusions: Dupilumab provided rapid, sustained improvement across both groups. Despite greater baseline severity and slower deep clearance achievement, IEI patients demonstrated substantial durable benefit, supporting dupilumab use in selected IEI-associated atopic manifestations.
- 7 October 2026
- Published by MDPI AG in Preprints.org
Open AccessUse of Dupilumab in Pediatric Atopic Dermatitis and in Inborn Errors of Immunity-Associated Atopic Skin Disease: An Italian Society of Pediatric Research (SIRP) Multicenter Real-World Study
Background: Atopic dermatitis (AD) is generally considered polygenic but may occur as a predominant manifestation of inborn errors of immunity (IEI). Although dupilumab is effective in pediatric AD, evidence in IEI-associated severe atopic skin disease remains limited, with no longitudinal comparative studies available. We aimed to characterize clinical phenotype and compare effectiveness, quality-of-life, and safety of dupilumab in pediatric patients with severe polygenic AD and IEI-associated severe atopic skin disease. Methods: This multicenter retrospective observational study within the Italian Society of Pediatric Research Network included children and adolescents who initiated dupilumab before 18 years of age. Given IEI rarity, we accepted a numerically unbalanced but clinically meaningful cohort. Clinical outcomes were assessed longitudinally using EASI, pruritus NRS, and CDLQI scores. Achievement and maintenance of EASI-50/75/90 re-sponses were evaluated, together with adverse events and treatment discontinuation. Results: Among 127 patients, 116 had polygenic AD and 11 had IEI-associated disease. IEI patients more frequently had disease onset within 6 months (64% vs. 29%; p=0.037), severe recurrent infections (100% vs. 0%; p< 0.001), very elevated sIgE (91% vs. 14%; p< 0.001), and higher baseline EASI (median 50 vs. 25; p< 0.001). EASI, pruritus, and CDLQI improved significantly over time. EASI-50/75/90 were achieved by 88.2%/81.9%/66.1% and maintained by 84.3%/69.3%/47.2%. IEI patients showed steeper EASI decline but achieved EASI-75/90 later. Dupilumab was well tolerated with no unexpected safety signals. Conclusions: Dupilumab provided rapid, sustained improvement across both groups. Despite greater baseline severity and slower deep clearance achievement, IEI patients demonstrated substantial durable benefit, supporting dupilumab use in selected IEI-associated atopic manifestations.
- Open Access
- 9 June 2026
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 14, 1774399
Italian healthcare professionals' real-world experience with immunization in children of non-European origin: the Vax4globe survey
Introduction: Nowadays vaccine hesitancy represents a significant current global health threat, causing reduced vaccine coverage with relevant effects on vulnerable populations. This study explores Italian healthcare professionals' (HCPs) experience with immunization of non-European (non-EU) origin children to implement targeted strategies for higher vaccine coverage and a “vulnerables-friendly care”. Methods: The Vax4globe survey was administered to HCPs distributed throughout the Lazio Region from February to July 2024. The survey included HCPs' demographic data and twelve items investigating vaccine compliance and barriers of non-EU origin children in their clinical practice as well as potential strategies to increase immunization. Results: The survey included 101 HCPs, namely physicians and pediatricians working at vaccination centers and primary care services, caring for approximately 50,000–60,000 children overall, of which approximately 15,000 were of non–EU origin. As stated by HCPs, children's country of origin were mainly from countries in Asia (median 30%; range 0%–80%) and South America (median 20%; range 0%–30%). Of the HCPs, 88% (95% CI: 80.4–93.1) reported that ≤50% of non-EU origin parents were able to provide evidence of their children's immunizations and, according to 80% (95% CI: 71.4–86.8) of HCPs, the Italian National Vaccination Prevention Plan (PNPV) was appropriate in ≤50% of children at first assessment. Therefore, according to HCPs, the vaccination record of the country of origin is essential to verify the immunization status (57%), PNPV vaccines should be recommended according to patient's age and documented immunization status (62%), and priority should be given to mandatory vaccines in children under 7 years of age not compliant with the PNPV (96%). In our survey, adherence to PNPV vaccines was significantly higher than to Sars-CoV-2 vaccine in pediatric age patients (immunization adherence 90%: 42.5% PNPV vs. 0% Sars-CoV-2) ( p < 0.0001). Similarly, the adherence to Sars-CoV-2 vaccine was lower in children than in their parents (immunization adherence p < 0.0001). Finally, according to HCPs, the main barriers to vaccine adherence were linguistic and socio-cultural (75%;95% CI: 66.0–82.6) for PNPV vaccines and safety concerns (52%; 95% CI: 42.8–61.9) for the Sars-CoV-2 vaccine. Discussion: Our study reports a real-world picture of immunization among non-EU origin children by Italian HCPs and highlights the need for targeted strategies to overcome factors affecting vaccine hesitancy. To date, vaccine health equity is far from being achieved.
- 9 June 2026
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 14, 1774399
Open AccessItalian healthcare professionals' real-world experience with immunization in children of non-European origin: the Vax4globe survey
Introduction: Nowadays vaccine hesitancy represents a significant current global health threat, causing reduced vaccine coverage with relevant effects on vulnerable populations. This study explores Italian healthcare professionals' (HCPs) experience with immunization of non-European (non-EU) origin children to implement targeted strategies for higher vaccine coverage and a “vulnerables-friendly care”. Methods: The Vax4globe survey was administered to HCPs distributed throughout the Lazio Region from February to July 2024. The survey included HCPs' demographic data and twelve items investigating vaccine compliance and barriers of non-EU origin children in their clinical practice as well as potential strategies to increase immunization. Results: The survey included 101 HCPs, namely physicians and pediatricians working at vaccination centers and primary care services, caring for approximately 50,000–60,000 children overall, of which approximately 15,000 were of non–EU origin. As stated by HCPs, children's country of origin were mainly from countries in Asia (median 30%; range 0%–80%) and South America (median 20%; range 0%–30%). Of the HCPs, 88% (95% CI: 80.4–93.1) reported that ≤50% of non-EU origin parents were able to provide evidence of their children's immunizations and, according to 80% (95% CI: 71.4–86.8) of HCPs, the Italian National Vaccination Prevention Plan (PNPV) was appropriate in ≤50% of children at first assessment. Therefore, according to HCPs, the vaccination record of the country of origin is essential to verify the immunization status (57%), PNPV vaccines should be recommended according to patient's age and documented immunization status (62%), and priority should be given to mandatory vaccines in children under 7 years of age not compliant with the PNPV (96%). In our survey, adherence to PNPV vaccines was significantly higher than to Sars-CoV-2 vaccine in pediatric age patients (immunization adherence 90%: 42.5% PNPV vs. 0% Sars-CoV-2) ( p < 0.0001). Similarly, the adherence to Sars-CoV-2 vaccine was lower in children than in their parents (immunization adherence p < 0.0001). Finally, according to HCPs, the main barriers to vaccine adherence were linguistic and socio-cultural (75%;95% CI: 66.0–82.6) for PNPV vaccines and safety concerns (52%; 95% CI: 42.8–61.9) for the Sars-CoV-2 vaccine. Discussion: Our study reports a real-world picture of immunization among non-EU origin children by Italian HCPs and highlights the need for targeted strategies to overcome factors affecting vaccine hesitancy. To date, vaccine health equity is far from being achieved.
- Open Access
- 24 April 2026
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 22 (1) , 2661495
Pre-vaccination immune signatures of children with inborn errors of immunity associate with COVID-19 vaccine response
The emergence of SARS-CoV-2 in late 2019 led to a global pandemic, prompting unprecedented efforts to develop and deploy effective vaccines.1–3 The BNT162b2 mRNA COVID-19 vaccine has demonstrated h...
- 24 April 2026
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 22 (1) , 2661495
Open AccessPre-vaccination immune signatures of children with inborn errors of immunity associate with COVID-19 vaccine response
The emergence of SARS-CoV-2 in late 2019 led to a global pandemic, prompting unprecedented efforts to develop and deploy effective vaccines.1–3 The BNT162b2 mRNA COVID-19 vaccine has demonstrated h...
- Open Access
- 4 March 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (3) , e70308
IgE to cyclophilin Bet v 7 triggers mast cell activation and mediates cross‐reactivity with Ara h 18 in children with seasonal allergic rhinitis
Background: Panallergens are ubiquitously expressed molecules that may drive IgE sensitization across diverse allergen sources, thereby shaping complex clinical phenotypes such as asthma and pollen–food allergy syndrome (PFAS). Although several panallergen families have been extensively characterized, unexplained sensitization patterns are still observed in clinical practice. Cyclophilins, a conserved protein family, have recently been proposed as candidate panallergens; however, their molecular, clinical, and functional roles remain largely undefined. Methods: Within the Panallergens in Pediatrics (PAN‐PED) cohort, we investigated 100 Italian children with seasonal allergic rhinitis (SAR) for IgE sensitization to the cyclophilins Bet v 7 and Ara h 18. Functional assays were performed by sensitizing mast cells with patient sera ( n = 11) and assessing activation upon stimulation with increasing concentrations of recombinant Bet v 7 (rBet v 7), using CD63 expression as readout. Additional experiments evaluated the impact of heat treatment (60°C, 80°C, or 100°C) and saliva digestion on rBet v 7 activity. Results: rBet v 7 induced mast cell activation in a dose‐dependent manner, with peak responses at intermediate allergen concentrations, followed by attenuation at higher doses. rBet v 7 maintained functional activity after exposure to mild heat and saliva. A strong correlation was found between specific IgE levels to Bet v 7 and Ara h 18 ( r = 0.996, p < 0.0001). Conclusion: Bet v 7 has the functional capacity to activate mast cells and is resistant to mild heat and saliva digestion, supporting its role as a clinically relevant panallergen. In addition, Bet v 7 shows high similarity to cyclophilins from other plant sources and exhibits virtually identical IgE‐binding properties to Ara h 18. These findings suggest a potential rationale for considering the inclusion of cyclophilins into molecular diagnostic panels, particularly in children with SAR.
- 4 March 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (3) , e70308
Open AccessIgE to cyclophilin Bet v 7 triggers mast cell activation and mediates cross‐reactivity with Ara h 18 in children with seasonal allergic rhinitis
Background: Panallergens are ubiquitously expressed molecules that may drive IgE sensitization across diverse allergen sources, thereby shaping complex clinical phenotypes such as asthma and pollen–food allergy syndrome (PFAS). Although several panallergen families have been extensively characterized, unexplained sensitization patterns are still observed in clinical practice. Cyclophilins, a conserved protein family, have recently been proposed as candidate panallergens; however, their molecular, clinical, and functional roles remain largely undefined. Methods: Within the Panallergens in Pediatrics (PAN‐PED) cohort, we investigated 100 Italian children with seasonal allergic rhinitis (SAR) for IgE sensitization to the cyclophilins Bet v 7 and Ara h 18. Functional assays were performed by sensitizing mast cells with patient sera ( n = 11) and assessing activation upon stimulation with increasing concentrations of recombinant Bet v 7 (rBet v 7), using CD63 expression as readout. Additional experiments evaluated the impact of heat treatment (60°C, 80°C, or 100°C) and saliva digestion on rBet v 7 activity. Results: rBet v 7 induced mast cell activation in a dose‐dependent manner, with peak responses at intermediate allergen concentrations, followed by attenuation at higher doses. rBet v 7 maintained functional activity after exposure to mild heat and saliva. A strong correlation was found between specific IgE levels to Bet v 7 and Ara h 18 ( r = 0.996, p < 0.0001). Conclusion: Bet v 7 has the functional capacity to activate mast cells and is resistant to mild heat and saliva digestion, supporting its role as a clinically relevant panallergen. In addition, Bet v 7 shows high similarity to cyclophilins from other plant sources and exhibits virtually identical IgE‐binding properties to Ara h 18. These findings suggest a potential rationale for considering the inclusion of cyclophilins into molecular diagnostic panels, particularly in children with SAR.
- Open Access
Toward Universal Protection: A Comprehensive Review of Pneumococcal Disease, Emerging Vaccination Challenges and Future Perspectives
Streptococcus pneumoniae contributes significantly to morbidity, mortality, and healthcare costs worldwide due to severe Invasive Pneumococcal Disease (IPD), particularly among young children and vulnerable populations. This review critically examines the current state of pneumococcal disease epidemiology, the evolution of vaccine strategies, and persistent challenges to achieve global control of the disease. The implementation of Pneumococcal Conjugate Vaccines (PCVs) has yielded substantial public health gains, establishing herd protection and sharply reducing vaccine-type IPD incidence. However, this success has been fundamentally challenged by serotype replacement, where non-vaccine serotypes have subsequently emerged to cause a significant proportion of the residual disease burden. This epidemiological shift has necessitated the development and deployment of higher-valency PCVs (PCV15, PCV20, and PCV21) to expand serotype coverage. Furthermore, optimal protection requires personalized strategies for high-risk cohorts where vaccine effectiveness can be compromised. In this context, the review details how pneumococcal vaccination—and particularly PPSV23—serves as an indispensable diagnostic tool to evaluate a broad spectrum of Inborn Errors of Immunity (IEI) and in particular humoral defects. Diagnostic challenges are strained by non-standardized assays and the limited panel of unique serotypes available for testing in the PCV era. The scientific priority is now the development of universal protein-based vaccines, to provide protection against all serotypes and non-encapsulated strains by targeting conserved virulence factors. This integrated approach, combining expanded PCV coverage with novel vaccine technology, is essential to mitigate the ongoing public health burden of pneumococcal disease.
Open AccessToward Universal Protection: A Comprehensive Review of Pneumococcal Disease, Emerging Vaccination Challenges and Future Perspectives
Streptococcus pneumoniae contributes significantly to morbidity, mortality, and healthcare costs worldwide due to severe Invasive Pneumococcal Disease (IPD), particularly among young children and vulnerable populations. This review critically examines the current state of pneumococcal disease epidemiology, the evolution of vaccine strategies, and persistent challenges to achieve global control of the disease. The implementation of Pneumococcal Conjugate Vaccines (PCVs) has yielded substantial public health gains, establishing herd protection and sharply reducing vaccine-type IPD incidence. However, this success has been fundamentally challenged by serotype replacement, where non-vaccine serotypes have subsequently emerged to cause a significant proportion of the residual disease burden. This epidemiological shift has necessitated the development and deployment of higher-valency PCVs (PCV15, PCV20, and PCV21) to expand serotype coverage. Furthermore, optimal protection requires personalized strategies for high-risk cohorts where vaccine effectiveness can be compromised. In this context, the review details how pneumococcal vaccination—and particularly PPSV23—serves as an indispensable diagnostic tool to evaluate a broad spectrum of Inborn Errors of Immunity (IEI) and in particular humoral defects. Diagnostic challenges are strained by non-standardized assays and the limited panel of unique serotypes available for testing in the PCV era. The scientific priority is now the development of universal protein-based vaccines, to provide protection against all serotypes and non-encapsulated strains by targeting conserved virulence factors. This integrated approach, combining expanded PCV coverage with novel vaccine technology, is essential to mitigate the ongoing public health burden of pneumococcal disease.
- Open Access
- 20 November 2025
- Published by MDPI AG in Preprints.org
Toward Universal Protection: A Comprehensive Review of Pneumococcal Disease, Emerging Vaccination Challenges and Future Perspectives
Streptococcus pneumoniae contributes significantly to morbidity, mortality, and healthcare costs worldwide due to severe Invasive Pneumococcal Disease (IPD), particularly among young children and vulnerable populations. This review critically examines the current state of pneumococcal disease epidemiology, the evolution of vaccine strategies, and persistent challenges to achieve global control of the disease. The implementation of Pneumococcal Conjugate Vaccines (PCVs) has yielded substantial public health gains, establishing herd immunity and sharply reducing vaccine-type IPD incidence. However, this success has been fundamentally challenged by serotype replacement, where non-vaccine serotypes have subsequently emerged to cause a significant proportion of the residual disease burden. This epidemiological shift has necessitated the development and deployment of higher-valency PCVs (PCV15, PCV20, and PCV21) to expand serotype coverage. Furthermore, optimal protection requires personalized strategies for high-risk cohorts where vaccine effectiveness can be compromised. In this context, the review details how pneumococcal vaccination - and particularly PPSV23 - serves as an indispensable diagnostic tool to evaluate a broad spectrum of Inborn Errors of Immunity (IEI) and in particular humoral defects. Diagnostic challenges are strained by non-standardized assays and the limited panel of unique serotypes available for testing in the PCV era. The scientific priority is now the development of universal protein-based vaccines, to provide protection against all serotypes and non-encapsulated strains by targeting conserved virulence factors. This integrated approach, combining expanded PCV coverage with novel vaccine technology, is essential to mitigate the ongoing public health burden of pneumococcal disease.
- 20 November 2025
- Published by MDPI AG in Preprints.org
Open AccessToward Universal Protection: A Comprehensive Review of Pneumococcal Disease, Emerging Vaccination Challenges and Future Perspectives
Streptococcus pneumoniae contributes significantly to morbidity, mortality, and healthcare costs worldwide due to severe Invasive Pneumococcal Disease (IPD), particularly among young children and vulnerable populations. This review critically examines the current state of pneumococcal disease epidemiology, the evolution of vaccine strategies, and persistent challenges to achieve global control of the disease. The implementation of Pneumococcal Conjugate Vaccines (PCVs) has yielded substantial public health gains, establishing herd immunity and sharply reducing vaccine-type IPD incidence. However, this success has been fundamentally challenged by serotype replacement, where non-vaccine serotypes have subsequently emerged to cause a significant proportion of the residual disease burden. This epidemiological shift has necessitated the development and deployment of higher-valency PCVs (PCV15, PCV20, and PCV21) to expand serotype coverage. Furthermore, optimal protection requires personalized strategies for high-risk cohorts where vaccine effectiveness can be compromised. In this context, the review details how pneumococcal vaccination - and particularly PPSV23 - serves as an indispensable diagnostic tool to evaluate a broad spectrum of Inborn Errors of Immunity (IEI) and in particular humoral defects. Diagnostic challenges are strained by non-standardized assays and the limited panel of unique serotypes available for testing in the PCV era. The scientific priority is now the development of universal protein-based vaccines, to provide protection against all serotypes and non-encapsulated strains by targeting conserved virulence factors. This integrated approach, combining expanded PCV coverage with novel vaccine technology, is essential to mitigate the ongoing public health burden of pneumococcal disease.
- Open Access
- 2 November 2025
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 36 (11) , e70225
Italian pediatric experts' consensus statement on diagnosis and management of primary atopic disorders
Background: Primary Atopic Disorders (PAD) represent a recently recognized subset of inborn errors of immunity (IEI), characterized by severe atopy driven by genetic mutations leading to dysregulated type 2 immune responses, excessive mast cell activation, and hyper production of IgE. In PAD patients, severe atopic manifestations, including eczema, asthma, food allergies, and eosinophilic gastrointestinal disorders, are often associated with other signs of immune dysfunction. Methods: Recognizing the need for standardized diagnostic and management guidelines for PAD, a Delphi‐based expert consensus was developed within the Immunology Committee of the Italian Society of Pediatric Allergy and Immunology (SIAIP). After a systematic review of the literature and the development of the clinical statements, 45 specialists from multiple pediatric subspecialties reached an agreement on key aspects of PAD classification, diagnosis, and treatment. Results: The consensus focuses on some red flags that could aid clinicians in suspecting PAD. The document also proposes a diagnostic work‐up to differentiate monogenic PAD from polygenic allergic conditions. It also emphasizes the importance of molecular pathway analysis to direct precision treatments, including biological drugs. Given the complexity of the field and the potential overlap between PAD and other IEI, the consensus recommends a multidisciplinary approach to diagnosis and treatment. The document establishes a framework for early recognition of PAD, integrating emerging genetic insights into clinical practice and promoting personalized therapeutic strategies. Conclusions: The present work is the first structured consensus to standardize PAD diagnosis and management among pediatric subspecialists, aiming to improve patient outcomes through early intervention and tailored therapies.
- 2 November 2025
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 36 (11) , e70225
Open AccessItalian pediatric experts' consensus statement on diagnosis and management of primary atopic disorders
Background: Primary Atopic Disorders (PAD) represent a recently recognized subset of inborn errors of immunity (IEI), characterized by severe atopy driven by genetic mutations leading to dysregulated type 2 immune responses, excessive mast cell activation, and hyper production of IgE. In PAD patients, severe atopic manifestations, including eczema, asthma, food allergies, and eosinophilic gastrointestinal disorders, are often associated with other signs of immune dysfunction. Methods: Recognizing the need for standardized diagnostic and management guidelines for PAD, a Delphi‐based expert consensus was developed within the Immunology Committee of the Italian Society of Pediatric Allergy and Immunology (SIAIP). After a systematic review of the literature and the development of the clinical statements, 45 specialists from multiple pediatric subspecialties reached an agreement on key aspects of PAD classification, diagnosis, and treatment. Results: The consensus focuses on some red flags that could aid clinicians in suspecting PAD. The document also proposes a diagnostic work‐up to differentiate monogenic PAD from polygenic allergic conditions. It also emphasizes the importance of molecular pathway analysis to direct precision treatments, including biological drugs. Given the complexity of the field and the potential overlap between PAD and other IEI, the consensus recommends a multidisciplinary approach to diagnosis and treatment. The document establishes a framework for early recognition of PAD, integrating emerging genetic insights into clinical practice and promoting personalized therapeutic strategies. Conclusions: The present work is the first structured consensus to standardize PAD diagnosis and management among pediatric subspecialists, aiming to improve patient outcomes through early intervention and tailored therapies.
- Open Access
Maternal Immunization: Current Evidence, Progress, and Challenges
Maternal immunization is a key strategy for protecting pregnant individuals and newborns from infectious diseases. This review examines the mechanisms and benefits of maternal immunization, with a focus on transplacental IgG transfer and immune system interactions. We provide an overview of current recommendations and the safety and efficacy profiles of maternal vaccines, including influenza, tetanus–diphtheria–acellular pertussis (Tdap), respiratory syncytial virus (RSV), COVID-19, and hepatitis B. Additionally, we analyze the barriers to maternal immunization, such as misinformation, vaccine hesitancy, and disparities in healthcare access, while exploring potential strategies to overcome these challenges through targeted educational initiatives, improved provider communication, and policy-driven interventions aimed at increasing vaccine confidence and accessibility. Finally, this review highlights recent innovations and future directions in maternal immunization, including emerging vaccines for Group B Streptococcus and cytomegalovirus. Expanding immunization programs and advancing research on maternal–fetal immunity are essential to optimizing vaccination strategies, improving public health outcomes, and reducing the global burden of infectious diseases.
Open AccessMaternal Immunization: Current Evidence, Progress, and Challenges
Maternal immunization is a key strategy for protecting pregnant individuals and newborns from infectious diseases. This review examines the mechanisms and benefits of maternal immunization, with a focus on transplacental IgG transfer and immune system interactions. We provide an overview of current recommendations and the safety and efficacy profiles of maternal vaccines, including influenza, tetanus–diphtheria–acellular pertussis (Tdap), respiratory syncytial virus (RSV), COVID-19, and hepatitis B. Additionally, we analyze the barriers to maternal immunization, such as misinformation, vaccine hesitancy, and disparities in healthcare access, while exploring potential strategies to overcome these challenges through targeted educational initiatives, improved provider communication, and policy-driven interventions aimed at increasing vaccine confidence and accessibility. Finally, this review highlights recent innovations and future directions in maternal immunization, including emerging vaccines for Group B Streptococcus and cytomegalovirus. Expanding immunization programs and advancing research on maternal–fetal immunity are essential to optimizing vaccination strategies, improving public health outcomes, and reducing the global burden of infectious diseases.
- Open Access
Vaccinations in Pediatric Hematology and Oncology: Biologic Basis, Clinical Applications, and Perspectives
Children with hemato-oncological diseases represent a heterogeneous population at heightened risk for vaccine-preventable diseases. Their immunosuppressed state reduces vaccine efficacy and raises safety concerns regarding live attenuated vaccines due to the risk of viral reactivation. The immunological and clinical implications of the single conditions are significantly different; therefore, specific vaccination strategies are needed. Despite the availability of vaccine guidelines for immunocompromised patients, clinical practice remains highly variable. It is generally recommended to avoid vaccinations during chemotherapy, with some exceptions for influenza, pneumococcal, and, in some countries, hepatitis B vaccines. The timing of immune recovery after chemotherapy depends on the specific treatment and most guidelines recommend administering vaccines 3–6 months after treatment cessation. Concerning HSCT, the timing of immune recovery is affected by several factors such as the HSCT platform, graft-versus-host disease (GvHD), and infections. Inactivated vaccines are typically administered 3–6 months post-HSCT, while live attenuated vaccines are delayed for at least two years. In children with asplenia or hyposplenism, recommendations focus on immunization against encapsulated bacteria, with tailored schedules based on the patient’s age and underlying condition. This paper explores the biological factors influencing vaccination efficacy and safety in pediatric hematology and oncology patients. It also provides an updated overview of the available evidence and current vaccination guidelines. Finally, this paper highlights the main clinical and research areas for further improvement to provide tailored vaccination schedules for this vulnerable population.
Open AccessVaccinations in Pediatric Hematology and Oncology: Biologic Basis, Clinical Applications, and Perspectives
Children with hemato-oncological diseases represent a heterogeneous population at heightened risk for vaccine-preventable diseases. Their immunosuppressed state reduces vaccine efficacy and raises safety concerns regarding live attenuated vaccines due to the risk of viral reactivation. The immunological and clinical implications of the single conditions are significantly different; therefore, specific vaccination strategies are needed. Despite the availability of vaccine guidelines for immunocompromised patients, clinical practice remains highly variable. It is generally recommended to avoid vaccinations during chemotherapy, with some exceptions for influenza, pneumococcal, and, in some countries, hepatitis B vaccines. The timing of immune recovery after chemotherapy depends on the specific treatment and most guidelines recommend administering vaccines 3–6 months after treatment cessation. Concerning HSCT, the timing of immune recovery is affected by several factors such as the HSCT platform, graft-versus-host disease (GvHD), and infections. Inactivated vaccines are typically administered 3–6 months post-HSCT, while live attenuated vaccines are delayed for at least two years. In children with asplenia or hyposplenism, recommendations focus on immunization against encapsulated bacteria, with tailored schedules based on the patient’s age and underlying condition. This paper explores the biological factors influencing vaccination efficacy and safety in pediatric hematology and oncology patients. It also provides an updated overview of the available evidence and current vaccination guidelines. Finally, this paper highlights the main clinical and research areas for further improvement to provide tailored vaccination schedules for this vulnerable population.